CRISPR Therapeutics AG (CRSP) — Stock Score Summary

CRISPR Therapeutics AG (CRSP) has a MoatMap StockRank of 23/100 based on Quality (29/100), Value (36/100), and Momentum (45/100) factor scores. The current signal is SELL. CRISPR Therapeutics is a pioneer in gene editing, but it remains a pre-profit speculative biotech company with a long, capital-intensive road to commercialization. It lacks the predictable owner earnings, high ROIC, and established moat required by our investment philosophy.

CRISPR Therapeutics AG is a leading gene editing company leveraging its proprietary CRISPR/Cas9 technology to develop transformative gene-based medicines for serious genetic diseases and cancers. As a pioneer in the field, it holds foundational intellectual property and has brought the first CRISPR-based gene therapy, Casgevy, to market, establishing a significant early competitive advantage.

Key Financial Metrics

Price$52.08
Market Cap$5.4B
P/E (Forward)-14.75
Price/Book3.03
Return on Equity-31.2%
Return on Invested Capital-31.4%
Debt/Equity43.41
Gross Margin0.0%
Operating Margin-8933.3%
Revenue Growth68.6%
Free Cash Flow$-261M

CRISPR Therapeutics AG operates in the Biotechnology industry, part of the Healthcare sector (Switzerland).

Frequently Asked Questions

What is CRISPR Therapeutics AG’s (CRSP) StockRank?
MoatMap’s StockRank for CRISPR Therapeutics AG (CRSP) is 23/100, with a Sell signal. It is a composite of Quality (29), Value (36), and Momentum (45) factor ranks across MoatMap’s 19,000+ stock universe.
Does CRISPR Therapeutics AG have an economic moat?
CRISPR Therapeutics AG (CRSP) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is CRISPR Therapeutics AG a buy, hold, or sell?
MoatMap’s current signal for CRISPR Therapeutics AG (CRSP) is Sell, based on a StockRank of 23/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is CRISPR Therapeutics AG in?
CRISPR Therapeutics AG (CRSP) operates in the Healthcare sector, specifically the Biotechnology industry (Switzerland).
Browse all ranked stocksCRSP deep dive reportAI ChampionsHow we score stocksSense-check another stock